A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer - Owensboro Health

Skip to Content

RTOG 0920

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Additional Information

Study

Location:             Owensboro Health

                             Mitchell Memorial Cancer Center

                             1020 Breckenridge Street

Owensboro, KY 42303

 

Study Phase:       Phase III

 

Cancer Type:       Head and Neck Cancer

 

Purpose:              This randomized Phase III clinical trial is to test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following head and neck surgery.

 

Enrollment and Eligibility:

 

Age:                     18 years or older

 

Disease:               Pathologically proven diagnosis of squamous cell carcinoma of the head/neck (oral cavity, oropharynx or larynx), with gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration.     

                          

Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases.

 

 

Contact Person:  Judy Strobel, RN, BSN, OCN, CCRP

                        Robin Osborne

                              Clinical Trials Coordinator

                             Phone:  (270) 691-8094

                                        (270) 688-1938

                             Fax:  (270) 688-3673

                             Email:  Judith.strobel@owensboro health.org

IRB Protocol Number
13034551.0